Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Device

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,206 result(s) found for: Device. Displaying page 52 of 211.
    «« First « Previous 48  49  50  51  52  53  54  55  56  Next» Last»»
    EudraCT Number: 2021-005499-20 Sponsor Protocol Number: RM21 Start Date*: 2022-07-05
    Sponsor Name:Research Maatschap Cardiologen Rotterdam Zuid
    Full Title: COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients treated with OCT-guided vs aNgio-guided completE revascul...
    Medical condition: ST elevated myocard infarction followed by PCI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004003-31 Sponsor Protocol Number: SQUINT-FoRT04 Start Date*: 2017-03-22
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of Nivolumab plus Ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or rec...
    Medical condition: Patients with Stage IIIB-not amenable to radical treatment or Stage IV metastatic or recurrent squamous-cell lung carcinoma (SqLC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041826 Squamous cell carcinoma of lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002958-21 Sponsor Protocol Number: HCV-art Start Date*: 2017-05-16
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Study HCV-art: An Open-Label, pilot Study, to Explore the Clinical Safety and Efficacy of Sofosbuvir/Ledipasvir in Hepatitis C Virus (HCV) Chronic Patients with Arthritis
    Medical condition: Chronic HCV associated with chronic arthritis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10066550 Chronic arthritis LLT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003762-13 Sponsor Protocol Number: NIO-0002 Start Date*: 2022-07-05
    Sponsor Name: Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB)
    Full Title: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH METASTASES (ANNA-SARC)
    Medical condition: soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-007265-20 Sponsor Protocol Number: IPH1101-205 Start Date*: 2008-03-06
    Sponsor Name:Innate Pharma
    Full Title: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients wit...
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006574-23 Sponsor Protocol Number: AR101-PREVEnt Start Date*: 2022-08-30
    Sponsor Name:Aytu BioPharma, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 ...
    Medical condition: vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014316 Ehlers-Danlos syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) BE (Prematurely Ended) FR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003208-42 Sponsor Protocol Number: CA209-6GE Start Date*: 2022-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage...
    Medical condition: Resected Stage IIIA/B/C/D or Stage IV melanoma in an adjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) BE (Completed) PL (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003543-11 Sponsor Protocol Number: 16-214-02 Start Date*: 2017-07-10
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad...
    Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-005057-36 Sponsor Protocol Number: GLG-801-07 Start Date*: 2018-05-17
    Sponsor Name:GLG Pharma S.A.
    Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant...
    Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038390 Renal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001172-36 Sponsor Protocol Number: DX211 Start Date*: 2017-08-09
    Sponsor Name:Oculis ehf.
    Full Title: Efficacy and safety of dexamethasone nanoparticles eye drops in diabetic macular edema.
    Medical condition: Diabaetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10012662 Diabetic eye disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2006-007029-29 Sponsor Protocol Number: DC0034 CR 301 Start Date*: 2007-05-08
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: NON-INFERIORITY STUDY OF A METRONIDAZOLE 0.75% CREAM VERSUS REFERENCE THERAPY IN THE LOCAL TREATMENT OF PAPULOPUSTULAR ROSACEA.
    Medical condition: Papulopustular Rosacea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FR (Completed) AT (Completed) DE (Completed) LV (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003216-30 Sponsor Protocol Number: 309544 Start Date*: 2005-11-14
    Sponsor Name:Schering AG
    Full Title: Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimes with 3 doses of ZK 219477 (16 and 12 mg/m² body ...
    Medical condition: Histologically proven metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) SI (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020611-36 Sponsor Protocol Number: AGLU07310 Start Date*: 2011-10-12
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003597-10 Sponsor Protocol Number: CRH103390 Start Date*: 2006-11-04
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
    Medical condition: Social Anxiety Disorder (SocAD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041242 Social anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005848-16 Sponsor Protocol Number: CS7017-A-E201 Start Date*: 2009-06-16
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS-7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY
    Medical condition: Stage III and IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000347-29 Sponsor Protocol Number: 060201 Start Date*: 2005-12-22
    Sponsor Name:Baxter AG
    Full Title: ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A
    Medical condition: Severe or moderately severe hemophilia A with a residual factor FVIII activity less than or equal 2%
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) HU (Completed) CZ (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004586-34 Sponsor Protocol Number: CVAA489A2404 Start Date*: 2007-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) DE (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004409-34 Sponsor Protocol Number: ESN364-PCO-201 Start Date*: 2015-01-21
    Sponsor Name:Ogeda S.A
    Full Title: Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Po...
    Medical condition: Polycystic Ovarian Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001982-33 Sponsor Protocol Number: E2090-E044-401 Start Date*: 2005-09-05
    Sponsor Name:Eisai Limited
    Full Title: An open label study of Zonegran (zonisamide) in patients with partial onset seizures.
    Medical condition: Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061334 pt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) DK (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002196-15 Sponsor Protocol Number: DSC127-2012-02 Start Date*: 2015-07-29
    Sponsor Name:Derma Sciencs Inc
    Full Title: A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Aclerastide (DSC127) in Treating Non-healing Foot U...
    Medical condition: Diabetic Foot Ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 48  49  50  51  52  53  54  55  56  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 23:48:18 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA